Libon-D3 should not be administered to patients.
- With a tendency to the formation of kidney stones containing calcium, also in the anamnesis;
- With pseudohypoparathyroidism ( the demand of vitamin D can be reduced due to the temporarily normal vitamin D sensitivity with the risk of a long-lasting overdose)
Libon-D3 should be administered only with caution to patients.
- With impaired renal calcium and phosphate excretion, in case of treatment with benzothiadiazine derivatives and immobilized patients, e.g. dut to cast (risk of hypercalcemia & hypercalciuria).
- Suffering from sarcoidosis because the risk of transformation of vitamin D into its active metabolites is increased. The calcium levels in serum and urine should be monitored in these patients.
During a long-term therapy with libon D3, the calcium levels in serum and urine should be monitored every 3 to 6 months, and the kidney function should be checked by measuring the serum creatinine. This check is particularly important in older patients and during a concomitant the serum creatinine. This check is particularly important in older patients and during concomitant therapy with cardiac glycosides or diuretics. In case of hypercalcemia or symptoms of impaired kidney function, the dosage must be reduced or the therapy is stopped. It is recommended to reduce the dosage or interrupt the therapy if the calcium level in the urine exceeds 7.5 mmol/24 hours ( 300 mg/24 hours). If other drugs containing Vitamin D are prescribed, the dosage of vitamin D from Libon D3 must be taken into account. Additional administration of vitamin D or calcium should only be carried out under medical supervision. In such cases, the calcium levels in serum and urine must be monitored.. In patients with renal insufficiency, that is treated with libon D3 the effect on the calcium and phosphate level should be monitored. Libon D3 should not be administered to patients who suffer from rare hereditary fructose intolerance.